Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Ref Type | |
PMID | |
Authors | A Drilon, F Barlesi, F D Braud, B C Cho, M-J Ahn, S Siena, MG. Krebs, C-C Lin, T John, DSW Tan, T Seto, R Dziadziuszko, H-T Arkenau, C Rolfo, J Wolf, C Ye, T Riehl, S Eng and RC. Doebele |
Title | Entrectinib in locally advanced or metastatic ROS1 fusion-positive non-small cell lung cancer (NSCLC): Integrated analysis of ALKA-372-001, STARTRK-1 and STARTRK-2 |
Journal | Cancer Res |
Vol | |
Issue | |
Date | |
URL | https://cancerres.aacrjournals.org/content/79/13_Supplement/CT192 |
Abstract Text | Cancer Res 2019;79(13 Suppl):Abstract nr CT192. |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
ROS1 positive | lung non-small cell carcinoma | sensitive | Entrectinib | FDA approved | Actionable | In a combined analysis of 3 clinical trials (ALKA-372-001, STARTRK-1, STARTRK-2) that supported FDA approval, Rozlytrek (entrectinib) treatment resulted in an objective response rate of 77% (41/53), a median duration of response of 25 months in patients with ROS1 fusion positive non-small cell lung cancer, with median progression-free survival of 26 and 14 months for patients without (n=30) and with (n=23) CNS disease, respectively (Cancer Res 2019;79(13 Suppl):Abstract nr CT192; NCT02097810; NCT02568267). | detail... detail... |